Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ATRIA IN CONNECTION WITH SALE OF FALBYGDENS OST
Mandate

VINGE ADVISES ATRIA IN CONNECTION WITH SALE OF FALBYGDENS OST

October 16, 2014

Vinge has advised Atria Sverige in connection with the sale of Falbygdens Ost to Arla Foods. Falbygdens Ost does not have its own cheese production facilities but, rather, buys cheese from other producers. Falbygdens Ost has approximately 100 employees and a turnover of approximately SEK 470 million. The transaction is subject to approval by the Swedish Competition Authority.

Vinge’s team consisted of partner Johan Winnerblad together with, among others, associates Alex Miler, Daniel Unger and Malin Buch as well as project assistant Josefin Backlund. Partner Johan Karlsson and associate Emil Fahlén Godö provided competition law advice.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026